If you have been reading my column the past few years, you are probably well aware of the mental health provider shortage in Nevada. Provider shortages in any field are problematic for a myriad of reasons, the main one being access. Without access, it is extremely difficult to receive timely care. A program called BeHERENV ...

Newly released state enrollment data show ObamaCare coverage losses could be even more severe than initially anticipated, due to Congress’s unwillingness to renew enhanced subsidies. Monthly enrollment data through April from Arkansas, Colorado, Maryland, Massachusetts, New Mexico and New York showed a significant number of people canceled their coverage or did not pay their premium bills after signing up for coverage in 2026, according to an analysis from Georgetown University. Federal officials have so far only released data ...

The NFIB Small Business Optimism Index fell 0.6 points in May to 95.3, remaining below its 52-year average of 98.0. The Uncertainty Index rose 3 points from April to 91, remaining well above its historical average of 68. As reported in NFIB’s monthly Jobs Report, the NFIB Small Business Employment Index remained essentially flat, registering 100.3 in May. ...

The state constitution requires a new budget to be adopted by June 15, leaving little time for Newsom and legislative leaders to resolve many billions of dollars in differences, particularly those involving health and social welfare services.

President Trump on Friday announced that over 100 prescription medications would be added to his administration’s direct-to-consumer drug platform, TrumpRx, the second expansion of the initiative in as many months. “I am pleased to announce that TrumpRx.gov is adding another 160 Prescription Drugs, at highly discounted prices, for a new total of over 800 of the most commonly-used Prescription Drugs,” ...

GLP-1 drugs are a double-edged sword for the nation’s employers. Although they are having a demonstrable effect on workplace health, the high cost is putting a strain on their budgets. GLP-1s, known by brand names such as Ozempic, Wegovy, Mounjaro or Zepbound, originally were developed to help regulate blood sugar in people with Type 2 ...